BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34196676)

  • 1. Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia.
    Hongeng S; Anurathapan U; Songdej D; Phuphuakrat A; Jongrak K; Parsons G; Deary B; Bonner M; Veres G; Asmal M
    Blood Adv; 2021 Jul; 5(13):2701-2706. PubMed ID: 34196676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Betibeglogene Autotemcel Gene Therapy for Non-β
    Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
    N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
    Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
    N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
    Sii-Felice K; Giorgi M; Leboulch P; Payen E
    Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.
    Persons DA; Hargrove PW; Allay ER; Hanawa H; Nienhuis AW
    Blood; 2003 Mar; 101(6):2175-83. PubMed ID: 12411297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease.
    Negre O; Bartholomae C; Beuzard Y; Cavazzana M; Christiansen L; Courne C; Deichmann A; Denaro M; de Dreuzy E; Finer M; Fronza R; Gillet-Legrand B; Joubert C; Kutner R; Leboulch P; Maouche L; Paulard A; Pierciey FJ; Rothe M; Ryu B; Schmidt M; von Kalle C; Payen E; Veres G
    Curr Gene Ther; 2015; 15(1):64-81. PubMed ID: 25429463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia.
    Hanawa H; Hargrove PW; Kepes S; Srivastava DK; Nienhuis AW; Persons DA
    Blood; 2004 Oct; 104(8):2281-90. PubMed ID: 15198957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene addition for beta thalassemia.
    Kwiatkowski JL
    Ann N Y Acad Sci; 2023 Dec; 1530(1):105-109. PubMed ID: 37828865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.
    Magrin E; Semeraro M; Hebert N; Joseph L; Magnani A; Chalumeau A; Gabrion A; Roudaut C; Marouene J; Lefrere F; Diana JS; Denis A; Neven B; Funck-Brentano I; Negre O; Renolleau S; Brousse V; Kiger L; Touzot F; Poirot C; Bourget P; El Nemer W; Blanche S; Tréluyer JM; Asmal M; Walls C; Beuzard Y; Schmidt M; Hacein-Bey-Abina S; Asnafi V; Guichard I; Poirée M; Monpoux F; Touraine P; Brouzes C; de Montalembert M; Payen E; Six E; Ribeil JA; Miccio A; Bartolucci P; Leboulch P; Cavazzana M
    Nat Med; 2022 Jan; 28(1):81-88. PubMed ID: 35075288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy.
    Li W; Xie S; Guo X; Gong X; Wang S; Lin D; Zhang J; Ren Z; Huang S; Zeng F; Zeng Y
    Haematologica; 2008 Mar; 93(3):356-62. PubMed ID: 18268280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.
    Malik P; Arumugam PI; Yee JK; Puthenveetil G
    Ann N Y Acad Sci; 2005; 1054():238-49. PubMed ID: 16339671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin gene therapy for β-thalassemia.
    Bank A
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1187-201. PubMed ID: 21075288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.
    Kansal AR; Reifsnider OS; Brand SB; Hawkins N; Coughlan A; Li S; Cragin L; Paramore C; Dietz AC; Caro JJ
    J Mark Access Health Policy; 2021 Jun; 9(1):1922028. PubMed ID: 34178295
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug product attributes predict clinical efficacy in betibeglogene autotemcel gene therapy for β-thalassemia.
    Whitney D; Shestopalov I; Fincker M; d'Anjou M; Kral K; Gayron M; Pierciey FJ; Colvin RA
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101155. PubMed ID: 38074412
    [No Abstract]   [Full Text] [Related]  

  • 15. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.
    Rivella S; May C; Chadburn A; Rivière I; Sadelain M
    Blood; 2003 Apr; 101(8):2932-9. PubMed ID: 12480689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
    Kanter J; Thompson AA; Pierciey FJ; Hsieh M; Uchida N; Leboulch P; Schmidt M; Bonner M; Guo R; Miller A; Ribeil JA; Davidson D; Asmal M; Walters MC; Tisdale JF
    Am J Hematol; 2023 Jan; 98(1):11-22. PubMed ID: 36161320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the transcriptional read-through rate of a lentiviral vector for β-thalassemia gene therapy.
    Wu J; Chen Y; Shen W; Zhang J; Zeng F
    J Gene Med; 2024 Jan; 26(1):e3640. PubMed ID: 37989259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.
    Imren S; Payen E; Westerman KA; Pawliuk R; Fabry ME; Eaves CJ; Cavilla B; Wadsworth LD; Beuzard Y; Bouhassira EE; Russell R; London IM; Nagel RL; Leboulch P; Humphries RK
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14380-5. PubMed ID: 12391330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel BaEVRless-Pseudotyped γ-Globin Lentiviral Vector Drives High and Stable Fetal Hemoglobin Expression and Improves Thalassemic Erythropoiesis
    Drakopoulou E; Georgomanoli M; Lederer CW; Kleanthous M; Costa C; Bernadin O; Cosset FL; Voskaridou E; Verhoeyen E; Papanikolaou E; Anagnou NP
    Hum Gene Ther; 2019 May; 30(5):601-617. PubMed ID: 30324804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Therapy for beta-thalassemia.
    Malik P; Arumugam PI
    Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.